254 related articles for article (PubMed ID: 33509905)
61. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
62. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
63. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
64. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
[TBL] [Abstract][Full Text] [Related]
65. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
Xu Q; Liu Y; Wang S; Wang J; Liu L; Xu Y; Qin Y
BMC Cancer; 2022 Jun; 22(1):628. PubMed ID: 35672728
[TBL] [Abstract][Full Text] [Related]
66. MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway.
Wang AQ; Lv M; Xu YH; Xie PM; Dong YY
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9860-9868. PubMed ID: 33090389
[TBL] [Abstract][Full Text] [Related]
67. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
[TBL] [Abstract][Full Text] [Related]
68. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
69. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
Zhao JX; Liu H; Lv J; Yang XJ
Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086
[TBL] [Abstract][Full Text] [Related]
70. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.
Lin YC; Wen KC; Sung PL; Chou YT; Liew PL; Chen LY; Huang RL; Lai HC; Chang LT
J Ovarian Res; 2020 Dec; 13(1):143. PubMed ID: 33292376
[TBL] [Abstract][Full Text] [Related]
71. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
[TBL] [Abstract][Full Text] [Related]
72. Inhibition of Ca
Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
[TBL] [Abstract][Full Text] [Related]
73. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
74. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.
Liu J; Lin B; Hao Y; Qi Y; Zhu L; Li F; Liu D; Cong J; Zhang S; Iwamori M
J Exp Clin Cancer Res; 2009 Dec; 28(1):154. PubMed ID: 20003467
[TBL] [Abstract][Full Text] [Related]
75. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
76. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
77. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
78. CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.
Shen F; Zong ZH; Liu Y; Chen S; Sheng XJ; Zhao Y
Biomed Pharmacother; 2019 Jun; 114():108787. PubMed ID: 30925458
[TBL] [Abstract][Full Text] [Related]
79. Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway.
Fang Q; Naidu KA; Naidu KA; Zhao H; Sun M; Dan HC; Nasir A; Kaiser HE; Cheng JQ; Nicosia SV; Coppola D
Anticancer Res; 2006; 26(1A):203-9. PubMed ID: 16475700
[TBL] [Abstract][Full Text] [Related]
80. Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Stottrup C; Tsang T; Chin YR
Mol Cancer Ther; 2016 Aug; 15(8):1964-74. PubMed ID: 27297869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]